RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
RIGEL PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$46.72+0.75 (+1.63%)
Close on Oct 19, 2026
- Market cap
- $914.31M
- P/E (TTM)
- 2.9
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
87.7%
16M of 19M shares
Institutional holders
155
33 new, 26 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 3 sales
Net sold $305.87K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Soleus Capital Group, LLC | 968,108 | 5.20% | 13G (passive) | May 6, 2026 |
| Soleus Capital Master Fund, L.P. | 1,843,504 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Armistice Capital, LLC | 1,672,000 | 8.95% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 1,381,983 | 7.70% | 13G (passive) amendment | Mar 31, 2025 |
| Steven Boyd | 1,280,000 | 6.93% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 1,091,223 | 6.00% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RIGL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 1,939,818 | 10.38% | $75.89M | +170,911 | 0.00% |
| Soleus Capital Management, L.P. | 1,843,504 | 9.87% | $72.12M | +1,833,504 | 2.49% |
| Armistice Capital, LLC | 1,672,000 | 8.95% | $65.41M | +392,000 | 0.80% |
| State Street Corp | 1,039,994 | 5.57% | $40.68M | −80,244 | 0.00% |
| Vanguard Capital Management LLC | 785,107 | 4.20% | $30.71M | +20,914 | 0.00% |
| American Century Companies Inc | 741,718 | 3.97% | $29.02M | +197,287 | 0.01% |
| Lsv Asset Management | 721,666 | 3.86% | $28.23K | +120,159 | 0.05% |
| Acadian Asset Management LLC | 591,686 | 3.17% | $23.14K | −74,740 | 0.03% |
| D. E. Shaw & Co., Inc. | 542,539 | 2.90% | $21.22M | +96,861 | 0.01% |
| Geode Capital Management, LLC | 483,175 | 2.59% | $18.91M | +42,549 | 0.00% |
| Marshall Wace, Llp | 367,393 | 1.97% | $14.37M | −230,985 | 0.01% |
| CM Management, LLC | 250,000 | 1.34% | $9.78M | +15,000 | 6.51% |
| Vanguard Portfolio Management LLC | 233,728 | 1.25% | $9.14M | +86,193 | 0.00% |
| Dimensional Fund Advisors LP | 227,951 | 1.22% | $8.92M | −151,590 | 0.00% |
| Goldman Sachs Group Inc | 226,780 | 1.21% | $8.87M | −212,321 | 0.00% |
| Two Sigma Investments, LP | 207,578 | 1.11% | $8.12M | −198,229 | 0.01% |
| Nomura Asset Management International Inc. | 195,000 | 1.04% | $7.63M | New | 0.01% |
| Morgan Stanley | 186,049 | 1.00% | $7.28M | +87,181 | 0.00% |
| Charles Schwab Investment Management Inc | 154,627 | 0.83% | $6.05M | −22,223 | 0.00% |
| Northern Trust Corp | 146,381 | 0.78% | $5.73M | +11,811 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 155 | 16M | 87.7% | 33 / 52 | 55 / 26 | 4M | 4M |
| Q1 2026 | 150 | 16M | 85.7% | 16 / 68 | 46 / 46 | 4M | 3M |
| Q4 2025 | 184 | 16M | 86.2% | 46 / 63 | 63 / 25 | 4M | 2M |
| Q3 2025 | 164 | 15M | 80.4% | 52 / 51 | 45 / 9 | 5M | 4M |
| Q2 2025 | 121 | 14M | 74.4% | 19 / 42 | 36 / 16 | 2M | 2M |
| Q1 2025 | 118 | 14M | 74.9% | 23 / 41 | 37 / 20 | 3M | 1M |
| Q4 2024 | 116 | 12M | 64.7% | 38 / 43 | 19 / 11 | 2M | 2M |
| Q3 2024 | 89 | 12M | 63.9% | 24 / 28 | 22 / 16 | 4M | 1M |
| Q2 2024 | 82 | 10M | 55.7% | 82 / 0 | 0 / 0 | 10M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RIGL | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 650,331 | 3.48% | $25.44M | 0.24% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 594,889 | 3.18% | $18.14M | 0.07% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 555,846 | 2.98% | $21.74M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 481,966 | 2.58% | $18.85M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 212,415 | 1.14% | $8.31M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 201,443 | 1.08% | $7.42M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 172,468 | 0.92% | $6.75M | 0.05% | Jun 30, 2026 |
| Nomura Healthcare Fund | 160,000 | 0.86% | $6.26M | 0.83% | Jun 30, 2026 |
| iShares Biotechnology ETF | 126,160 | 0.68% | $4.94M | 0.05% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 94,115 | 0.50% | $2.87M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 91,913 | 0.49% | $2.80M | 0.02% | May 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 91,888 | 0.49% | $3.59M | 0.06% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 90,858 | 0.49% | $2.77M | 0.05% | May 29, 2026 |
| Schwab U.S. Small-Cap ETF | 89,359 | 0.48% | $2.72M | 0.01% | May 31, 2026 |
| Pacer US Small Cap Cash Cows 100 ETF | 84,790 | 0.45% | $3.12M | 0.09% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Raul R. Rodriguez | CEO, President, Director | 273,362 | 1.46% | Sep 3, 2026 |
| Raymond J. Furey | EVP, GC, CCO & Corp Sec | 50,559 | 0.27% | Sep 3, 2026 |
| David A. Santos | EVP, Chief Commercial Officer | 61,622 | 0.33% | Sep 3, 2026 |
| Dean L. Schorno | EVP & Chief Financial Officer | 79,676 | 0.43% | Sep 3, 2026 |
| Alison L. Hannah | EVP, Chief Medical Officer | 35,025 | 0.19% | Jul 10, 2026 |
| Lisa Rojkjaer | EVP, Chief Medical Officer | 34,003 | 0.18% | Jun 22, 2026 |
| Kamil Ali-Jackson | Director | 10,125 | 0.05% | Jun 24, 2026 |
| Mark W. Frohlich | Director | 7,000 | 0.04% | May 19, 2026 |
| Walter H. Moos | Director | 18,472 | 0.10% | May 19, 2026 |
| Michael Patrick Miller | Director | 5,937 | 0.03% | May 19, 2026 |
| Jane Wasman | Director | 18,250 | 0.10% | May 19, 2026 |
| Anthony Gregg Lapointe | Director | 18,250 | 0.10% | May 19, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dean L. Schorno EVP & Chief Financial Officer | Sep 2, 2026 | Option exercise | +620 | $18.70 | $11.59K | 79,676 |
| Dean L. Schorno EVP & Chief Financial Officer | Sep 2, 2026 | Option exercise | +2,000 | $24.20 | $48.40K | 81,676 |
| Dean L. Schorno EVP & Chief Financial Officer | Sep 2, 2026 | Option exercise | +1,286 | $24.20 | $31.12K | 82,962 |
| Dean L. Schorno EVP & Chief Financial Officer | Sep 2, 2026 | Option exercise | +694 | $12.70 | $8.81K | 79,056 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Sep 1, 2026 | Tax withholding | −877 | $47.50 | $41.66K | 50,559 |
| Raul R. Rodriguez CEO, President, Director | Sep 1, 2026 | Tax withholding | −2,424 | $47.50 | $115.14K | 273,362 |
| David A. Santos EVP, Chief Commercial Officer | Sep 1, 2026 | Tax withholding | −874 | $47.50 | $41.52K | 61,622 |
| Dean L. Schorno EVP & Chief Financial Officer | Sep 1, 2026 | Tax withholding | −928 | $47.50 | $44.08K | 78,362 |
| Alison L. Hannah EVP, Chief Medical Officer | Jul 8, 2026 | Award | +24,400 | – | – | 35,025 |
| Kamil Ali-Jackson Director | Jun 22, 2026 | Sale(10b5-1 plan) | −2,500 | $35.00 | $87.50K | 10,125 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Jun 1, 2026 | Tax withholding | −877 | $29.86 | $26.19K | 50,936 |
| Dean L. Schorno EVP & Chief Financial Officer | Jun 1, 2026 | Tax withholding | −928 | $29.86 | $27.71K | 78,790 |
| Dean L. Schorno EVP & Chief Financial Officer | Jun 1, 2026 | Option exercise | +2,181 | $12.70 | $27.70K | 79,718 |
| Dean L. Schorno EVP & Chief Financial Officer | Jun 1, 2026 | Option exercise | +1,200 | $18.70 | $22.44K | 77,537 |
| David A. Santos EVP, Chief Commercial Officer | Jun 1, 2026 | Tax withholding | −874 | $29.86 | $26.10K | 61,996 |
| Lisa Rojkjaer EVP, Chief Medical Officer | Jun 1, 2026 | Tax withholding | −850 | $29.86 | $25.38K | 34,003 |
| Raul R. Rodriguez CEO, President, Director | Jun 1, 2026 | Tax withholding | −2,424 | $29.86 | $72.38K | 279,593 |
| Kamil Ali-Jackson Director | May 26, 2026 | Sale(10b5-1 plan) | −2,500 | $29.17 | $72.93K | 12,625 |
| Walter H. Moos Director | May 15, 2026 | Award | +5,750 | – | – | 18,472 |
| Alison L. Hannah Director | May 15, 2026 | Award | +5,750 | – | – | 16,375 |
| Jane Wasman Director | May 15, 2026 | Award | +5,750 | – | – | 18,250 |
| Anthony Gregg Lapointe Director | May 15, 2026 | Award | +5,750 | – | – | 18,250 |
| Mark W. Frohlich Director | May 15, 2026 | Award | +5,750 | – | – | 7,000 |
| Michael Patrick Miller Director | May 15, 2026 | Award | +5,750 | – | – | 5,937 |
| Kamil Ali-Jackson Director | May 15, 2026 | Award | +5,750 | – | – | 15,125 |
| Walter H. Moos Director | Feb 20, 2026 | Sale | −4,000 | $36.36 | $145.44K | 12,722 |
| Walter H. Moos Director | Feb 20, 2026 | Option exercise | +4,000 | $24.00 | $96.00K | 16,722 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Feb 17, 2026 | Award | +19,497 | – | – | 51,813 |
| Lisa Rojkjaer EVP, Chief Medical Officer | Feb 17, 2026 | Award | +18,894 | – | – | 34,853 |
| Raul R. Rodriguez CEO, President, Director | Feb 17, 2026 | Award | +53,915 | – | – | 282,017 |
| David A. Santos EVP, Chief Commercial Officer | Feb 17, 2026 | Award | +19,430 | – | – | 62,870 |
| Dean L. Schorno EVP & Chief Financial Officer | Feb 17, 2026 | Award | +20,636 | – | – | 76,337 |
| David A. Santos EVP, Chief Commercial Officer | Feb 10, 2026 | Tax withholding | −3,546 | $34.62 | $122.76K | 43,440 |
| Raul R. Rodriguez CEO, President, Director | Feb 10, 2026 | Tax withholding | −7,607 | $34.62 | $263.35K | 228,102 |
| Dean L. Schorno EVP & Chief Financial Officer | Feb 10, 2026 | Tax withholding | −3,546 | $34.62 | $122.76K | 55,701 |
| Lisa Rojkjaer EVP, Chief Medical Officer | Feb 10, 2026 | Tax withholding | −3,758 | $34.62 | $130.10K | 15,959 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Feb 10, 2026 | Tax withholding | −3,546 | $34.62 | $122.76K | 32,316 |
| David A. Santos EVP, Chief Commercial Officer | Feb 2, 2026 | Tax withholding | −5,718 | $36.01 | $205.91K | 46,986 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Feb 2, 2026 | Tax withholding | −3,968 | $36.01 | $142.89K | 35,862 |
| Raul R. Rodriguez CEO, President, Director | Feb 2, 2026 | Tax withholding | −14,110 | $36.01 | $508.10K | 235,709 |
| Dean L. Schorno EVP & Chief Financial Officer | Feb 2, 2026 | Tax withholding | −5,488 | $36.01 | $197.62K | 59,247 |
| Raul R. Rodriguez CEO, President, Director | Jan 26, 2026 | Tax withholding | −35,211 | $37.00 | $1.30M | 245,243 |
| Raul R. Rodriguez CEO, President, Director | Jan 26, 2026 | Option exercise | +40,000 | $27.40 | $1.10M | 280,454 |
| Raul R. Rodriguez CEO, President, Director | Jan 26, 2026 | Option exercise | +40,000 | $27.40 | $1.10M | 285,243 |
| Raul R. Rodriguez CEO, President, Director | Jan 26, 2026 | Tax withholding | −35,424 | $37.00 | $1.31M | 249,819 |
| Dean L. Schorno EVP & Chief Financial Officer | Dec 22, 2025 | Option exercise | +1,987 | $20.00 | $39.74K | 59,722 |
| Dean L. Schorno EVP & Chief Financial Officer | Dec 22, 2025 | Option exercise | +2,846 | $24.20 | $68.87K | 62,568 |
| Dean L. Schorno EVP & Chief Financial Officer | Dec 22, 2025 | Option exercise | +1,667 | $18.70 | $31.17K | 64,235 |
| Walter H. Moos Director | May 23, 2025 | Award | +2,500 | – | – | 12,722 |
| Alison L. Hannah Director | May 23, 2025 | Award | +2,500 | – | – | 10,625 |
| Mark W. Frohlich Director | May 23, 2025 | Award | +1,250 | – | – | 1,250 |
| Kamil Ali-Jackson Director | May 23, 2025 | Award | +2,500 | – | – | 9,375 |
| Jane Wasman Director | May 23, 2025 | Award | +2,500 | – | – | 12,500 |
| Anthony Gregg Lapointe Director | May 23, 2025 | Award | +2,500 | – | – | 12,500 |
| David A. Santos EVP, Chief Commercial Officer | Feb 5, 2025 | Sale | −1,796 | $21.93 | $39.39K | 51,704 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Feb 5, 2025 | Sale | −1,339 | $21.93 | $29.36K | 38,830 |
| Raul R. Rodriguez CEO, President, Director | Feb 5, 2025 | Sale | −4,400 | $21.93 | $96.49K | 239,454 |
| Dean L. Schorno EVP & Chief Financial Officer | Feb 5, 2025 | Sale | −1,734 | $21.93 | $38.03K | 57,235 |
| David A. Santos EVP, Chief Commercial Officer | Feb 4, 2025 | Sale | −2,125 | $20.92 | $44.46K | 53,500 |
| Raymond J. Furey EVP, GC, CCO & Corp Sec | Feb 4, 2025 | Sale | −1,448 | $20.92 | $30.29K | 40,169 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kamil Ali-Jackson Director | Jun 22, 2026 | 2,500 | $87.50K | Jun 22, 2026 | Restricted Stock Vesting |
| Kamil Ali-Jackson Director | May 26, 2026 | 2,500 | $72.93K | May 26, 2026 | Restricted Stock Vesting |
| Walter H. Moos Director | Feb 20, 2026 | 4,000 | $145.44K | Feb 20, 2026 | Option Granted 05/11/2016 |
| Raymond J. Furey Officer | Feb 5, 2025 | 1,339 | $29.36K | Feb 5, 2025 | Restricted Stock Vesting |
| David A. Santos Officer | Feb 5, 2025 | 1,796 | $39.38K | Feb 5, 2025 | Restricted Stock Vesting |
| Raul R. Rodriguez Officer, Director | Feb 5, 2025 | 4,400 | $96.47K | Feb 5, 2025 | Restricted Stock Vesting |
| Dean L. Schorno Officer | Feb 5, 2025 | 1,734 | $38.02K | Feb 5, 2025 | Restricted Stock Vesting |
| Dean L. Schorno Officer | Feb 4, 2025 | 2,036 | $42.60K | Feb 4, 2025 | Restricted Stock Vesting |
| Raul R. Rodriguez Officer, Director | Feb 4, 2025 | 4,952 | $103.60K | Feb 4, 2025 | Restricted Stock Vesting |
| David A. Santos Officer | Feb 4, 2025 | 2,125 | $44.46K | Feb 4, 2025 | Restricted Stock Vesting |
| Raymond J. Furey Officer | Feb 4, 2025 | 1,448 | $30.29K | Feb 4, 2025 | Restricted Stock Vesting |
| Esteban Masuda Officer | Jan 24, 2025 | 4,999 | $110.68K | Jan 24, 2025 | Option Granted - 01/26/2015 |